Dimensional Fund Advisors LP Decreases Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Dimensional Fund Advisors LP lowered its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 12.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,157,960 shares of the biotechnology company’s stock after selling 440,076 shares during the period. Dimensional Fund Advisors LP owned approximately 1.36% of ADMA Biologics worth $35,305,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. LSV Asset Management bought a new position in ADMA Biologics in the 1st quarter valued at $1,028,000. BNP Paribas Financial Markets boosted its position in ADMA Biologics by 152.2% in the 1st quarter. BNP Paribas Financial Markets now owns 732,920 shares of the biotechnology company’s stock valued at $4,837,000 after buying an additional 442,315 shares during the period. Russell Investments Group Ltd. increased its position in shares of ADMA Biologics by 90.7% during the first quarter. Russell Investments Group Ltd. now owns 1,169,207 shares of the biotechnology company’s stock worth $7,717,000 after acquiring an additional 556,175 shares during the period. Inspire Investing LLC raised its stake in shares of ADMA Biologics by 125.2% during the first quarter. Inspire Investing LLC now owns 189,303 shares of the biotechnology company’s stock valued at $1,249,000 after acquiring an additional 105,256 shares in the last quarter. Finally, Calamos Advisors LLC boosted its holdings in shares of ADMA Biologics by 8.3% in the second quarter. Calamos Advisors LLC now owns 603,003 shares of the biotechnology company’s stock valued at $6,742,000 after purchasing an additional 46,405 shares during the period. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at ADMA Biologics

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the sale, the director now owns 153,941 shares in the company, valued at approximately $2,843,290.27. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, CEO Adam S. Grossman sold 236,889 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the transaction, the chief executive officer now directly owns 2,059,726 shares in the company, valued at $36,436,552.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Lawrence P. Guiheen sold 9,000 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the sale, the director now directly owns 153,941 shares in the company, valued at $2,843,290.27. The disclosure for this sale can be found here. Insiders have sold a total of 466,900 shares of company stock valued at $8,224,121 in the last ninety days. Company insiders own 3.70% of the company’s stock.

ADMA Biologics Price Performance

Shares of ADMA stock opened at $19.77 on Wednesday. The company has a market cap of $4.58 billion, a P/E ratio of -988.50 and a beta of 0.61. The company has a debt-to-equity ratio of 0.74, a current ratio of 6.87 and a quick ratio of 2.80. The stock’s 50-day moving average is $16.51 and its 200 day moving average is $11.56. ADMA Biologics, Inc. has a 1-year low of $3.06 and a 1-year high of $20.37.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.05. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The company had revenue of $107.20 million for the quarter, compared to analyst estimates of $86.44 million. During the same period in the prior year, the company posted ($0.02) EPS. The firm’s quarterly revenue was up 78.4% compared to the same quarter last year. Research analysts predict that ADMA Biologics, Inc. will post 0.49 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating and set a $20.00 price target on shares of ADMA Biologics in a research report on Friday, September 20th. Mizuho increased their target price on shares of ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, June 20th. Finally, HC Wainwright raised their target price on shares of ADMA Biologics from $10.00 to $18.00 and gave the company a “buy” rating in a research report on Monday, August 12th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, ADMA Biologics has a consensus rating of “Buy” and an average target price of $15.50.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.